PE20181044A1 - Anticuerpos anti-pd-1 y composiciones - Google Patents
Anticuerpos anti-pd-1 y composicionesInfo
- Publication number
- PE20181044A1 PE20181044A1 PE2018000485A PE2018000485A PE20181044A1 PE 20181044 A1 PE20181044 A1 PE 20181044A1 PE 2018000485 A PE2018000485 A PE 2018000485A PE 2018000485 A PE2018000485 A PE 2018000485A PE 20181044 A1 PE20181044 A1 PE 20181044A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- nos
- antibody
- antigen
- vector
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Se refiere a un anticuerpo anti-PD-1 o una porcion de union a antigeno del mismo, en donde el anticuerpo compite por la union a Proteina de Muerte Celular Programada 1 (PD-1) humana, o se une al mismo epitopo, cuyos dominios variables de cadena pesada y ligera comprenden las secuencias de aminoacidos de: a) SEQ ID Nos: 2 y 3, respectivamente; b) SEQ ID Nos: 4 y 5, respectivamente; c) SEQ ID Nos: 4 y 66, respectivamente; d) SEQ ID Nos: 6 y 7, respectivamente; e) SEQ ID Nos: 8 y 9, respectivamente; f) SEQ ID Nos: 10 y 11, respectivamente; g) SEQ ID Nos: 12 y 13, respectivamente; h) SEQ ID Nos: 14 y 15, respectivamente; i) SEQ ID Nos: 16 y 17, respectivamente. Ademas, se refiere a una molecula de acido nucleico aislada que comprende una secuencia de nucleotidos que codifica la cadena pesada o una porcion de union a antigeno, un vector que comprende la molecula de acido nucleico y una celula anfitriona que comprende el vector; y un metodo para producir dicho anticuerpo o una porcion de ella. Se usa en el tratamiento de enfermedades y afecciones relacionadas con la actividad de PD-1, como el cancer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562236341P | 2015-10-02 | 2015-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181044A1 true PE20181044A1 (es) | 2018-07-03 |
Family
ID=57042898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018000485A PE20181044A1 (es) | 2015-10-02 | 2016-09-30 | Anticuerpos anti-pd-1 y composiciones |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11034765B2 (es) |
| EP (2) | EP3368572B9 (es) |
| JP (1) | JP6875385B2 (es) |
| KR (1) | KR20180053752A (es) |
| CN (1) | CN108290953B (es) |
| AU (1) | AU2016333517B2 (es) |
| BR (1) | BR112018006257A2 (es) |
| CA (1) | CA3000564A1 (es) |
| CO (1) | CO2018003500A2 (es) |
| DK (1) | DK3368572T3 (es) |
| ES (1) | ES2924402T3 (es) |
| HR (1) | HRP20221041T1 (es) |
| HU (1) | HUE059788T2 (es) |
| IL (1) | IL258214B2 (es) |
| LT (1) | LT3368572T (es) |
| MX (1) | MX2018003936A (es) |
| MY (1) | MY190324A (es) |
| PE (1) | PE20181044A1 (es) |
| PL (1) | PL3368572T3 (es) |
| PT (1) | PT3368572T (es) |
| RS (1) | RS63490B1 (es) |
| RU (1) | RU2750675C1 (es) |
| SA (1) | SA518391262B1 (es) |
| SG (1) | SG10201912943RA (es) |
| SI (1) | SI3368572T1 (es) |
| TW (1) | TWI751981B (es) |
| WO (1) | WO2017055547A1 (es) |
| ZA (1) | ZA201801852B (es) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3875477A1 (en) | 2015-04-17 | 2021-09-08 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| EA201890285A1 (ru) | 2015-07-13 | 2018-08-31 | Сайтомкс Терапьютикс, Инк. | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения |
| CA2993276A1 (en) | 2015-08-11 | 2017-02-16 | Yong Zheng | Novel anti-pd-1 antibodies |
| CN107949573B (zh) | 2015-09-01 | 2022-05-03 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| MX2018003689A (es) | 2015-09-29 | 2018-04-30 | Celgene Corp | Proteinas de union a pd-1 y metodos para usarlas. |
| MA43186B1 (fr) | 2015-11-03 | 2022-03-31 | Janssen Biotech Inc | Anticorps se liant spécifiquement à pd-1 et leurs utilisations |
| JP2019521643A (ja) | 2016-04-15 | 2019-08-08 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｄ８０バリアント免疫調節タンパク質およびその使用 |
| BR112018070934A2 (pt) | 2016-04-15 | 2019-02-26 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras variantes ligantes de icos e usos das mesmas |
| MX2018016364A (es) | 2016-06-20 | 2019-11-28 | Kymab Ltd | Anticuerpos anti-pd-l1. |
| US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
| JP2019531284A (ja) | 2016-09-19 | 2019-10-31 | セルジーン コーポレイション | Ｐｄ−１結合タンパク質を使用して免疫障害を治療する方法 |
| BR112019005316A2 (pt) | 2016-09-21 | 2019-09-03 | Cstone Pharmaceutical Suzhou Co Ltd | anticorpos monoclonais para morte programada 1 (pd-1) |
| AU2017355401A1 (en) | 2016-11-02 | 2019-05-02 | Jounce Therapeutics, Inc. | Antibodies to PD-1 and uses thereof |
| US11359018B2 (en) | 2016-11-18 | 2022-06-14 | Symphogen A/S | Anti-PD-1 antibodies and compositions |
| WO2018133842A1 (zh) | 2017-01-20 | 2018-07-26 | 大有华夏生物医药集团有限公司 | 人程序性死亡受体pd-1的单克隆抗体及其片段 |
| BR112019018747A2 (pt) | 2017-03-16 | 2020-05-05 | Alpine Immune Sciences Inc | proteínas imunomoduladoras variantes de cd80 e usos das mesmas |
| MA49042A (fr) | 2017-04-05 | 2020-02-12 | Symphogen As | Polythérapies ciblant pd-1, tim-3 et lag-3 |
| CN106939049B (zh) * | 2017-04-20 | 2019-10-01 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用 |
| JP2020529862A (ja) * | 2017-06-25 | 2020-10-15 | システィミューン， インク．Ｓｙｓｔｉｍｍｕｎｅ， Ｉｎｃ． | 抗ｐｄ−１抗体とその作製及び使用方法 |
| JP2020533016A (ja) | 2017-08-01 | 2020-11-19 | エービー ストゥーディオ インコーポレイテッド | 二重特異性抗体およびその使用 |
| KR101917854B1 (ko) * | 2017-08-24 | 2018-11-12 | 한국콜마주식회사 | 세포 수용체 결합능이 있는 펩티드를 포함하는 마이크로 캡슐 및 이를 포함하는 화장료 조성물 |
| CN111712515A (zh) | 2017-10-18 | 2020-09-25 | 高山免疫科学股份有限公司 | 变体icos配体免疫调节蛋白及相关组合物和方法 |
| AR114127A1 (es) | 2018-03-02 | 2020-07-22 | Lilly Co Eli | Anticuerpos agonistas contra pd-1 y usos de estos |
| SG11202009986QA (en) | 2018-05-07 | 2020-11-27 | Genmab As | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| US20210363219A1 (en) * | 2018-06-15 | 2021-11-25 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| CN112424231B (zh) * | 2018-07-19 | 2022-09-13 | 大有华夏生物医药集团有限公司 | 抗pd-1抗体及其剂量和用途 |
| EP3823988A1 (en) * | 2018-07-19 | 2021-05-26 | Eli Lilly and Company | Bispecific antibodies targeting immune checkpoints |
| CA3109216A1 (en) * | 2018-08-16 | 2020-02-20 | Musc Foundation For Research Development | Recombinant myxoma viruses and uses thereof |
| TWI815964B (zh) * | 2018-09-14 | 2023-09-21 | 李蘭 史丹佛學院理事會 | sPD-1變異體–FC融合蛋白 |
| CN113015748A (zh) * | 2018-10-31 | 2021-06-22 | 默沙东公司 | 抗人pd-1抗体晶体及其使用方法 |
| WO2020127367A1 (en) * | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Humanized anti-human-pd-1 antibody |
| CN111349162A (zh) * | 2018-12-21 | 2020-06-30 | 神州细胞工程有限公司 | 人源化抗pd-1抗体及其用途 |
| AR118619A1 (es) * | 2019-04-10 | 2021-10-20 | Bio Thera Solutions Ltd | Anticuerpos de unión a pd-1 |
| TW202328206A (zh) | 2019-07-05 | 2023-07-16 | 日商小野藥品工業股份有限公司 | 以ｐｄ－１／ｃｄ３雙特異性蛋白質所進行之血液性癌症治療 |
| EP4011918A4 (en) | 2019-08-08 | 2023-08-23 | ONO Pharmaceutical Co., Ltd. | DUAL SPECIFIC PROTEIN |
| WO2021044005A1 (en) | 2019-09-06 | 2021-03-11 | Symphogen A/S | Anti-cd73 antibodies |
| EP4037700A2 (en) * | 2019-10-03 | 2022-08-10 | Xencor, Inc. | Targeted il-12 heterodimeric fc-fusion proteins |
| CN113244385A (zh) * | 2020-02-07 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗恶性肿瘤中的用途 |
| US20240024320A1 (en) | 2020-11-17 | 2024-01-25 | Seagen Inc. | Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody |
| JP2024508658A (ja) * | 2021-02-04 | 2024-02-28 | ジェヌーヴ インク． | 抗ｐｄ－１抗体及びその用途 |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| US20230051304A1 (en) | 2021-07-19 | 2023-02-16 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| WO2023022965A2 (en) | 2021-08-16 | 2023-02-23 | Regeneron Pharmaceuticals, Inc. | Novel il27 receptor agonists and methods of use thereof |
| AR127234A1 (es) | 2021-10-04 | 2024-01-03 | Servier Lab | Terapia del cáncer dirigida a nkg2a |
| CA3234647A1 (en) | 2021-10-06 | 2023-04-13 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination therapy |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| WO2023220647A1 (en) | 2022-05-11 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | Multispecific binding molecule proproteins and uses thereof |
| WO2023218046A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
| US20230382969A1 (en) | 2022-05-27 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
| WO2023235848A1 (en) | 2022-06-04 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
| WO2024040247A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon proproteins and uses thereof |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| KR101498834B1 (ko) | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| BRPI0715794A2 (pt) * | 2006-08-17 | 2013-07-23 | Hoffmann La Roche | conjugado de anticorpo contra ccr5 e peptÍdeo antifusogÊnico |
| PT2121920E (pt) | 2007-03-01 | 2011-10-03 | Symphogen As | Método de clonagem de anticorpos cognatos |
| US20100069262A1 (en) | 2008-08-29 | 2010-03-18 | Symphogen A/S | Method for Cloning Avian-Derived Antibodies |
| JP5794917B2 (ja) * | 2008-09-12 | 2015-10-14 | アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ | Ｐｄ−１特異抗体およびその使用 |
| US8927697B2 (en) * | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| LT2691112T (lt) | 2011-03-31 | 2018-07-25 | Merck Sharp & Dohme Corp. | Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| SG11201604738TA (en) | 2013-12-12 | 2016-07-28 | Shanghai Hengrui Pharm Co Ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| CA3175979A1 (en) | 2014-12-22 | 2016-06-30 | Pd-1 Acquisition Group, Llc | Anti-pd-1 antibodies |
-
2016
- 2016-09-30 MY MYPI2018701111A patent/MY190324A/en unknown
- 2016-09-30 IL IL258214A patent/IL258214B2/en unknown
- 2016-09-30 SG SG10201912943RA patent/SG10201912943RA/en unknown
- 2016-09-30 PE PE2018000485A patent/PE20181044A1/es unknown
- 2016-09-30 RU RU2018115979A patent/RU2750675C1/ru active
- 2016-09-30 HR HRP20221041TT patent/HRP20221041T1/hr unknown
- 2016-09-30 SI SI201631586T patent/SI3368572T1/sl unknown
- 2016-09-30 EP EP16774691.6A patent/EP3368572B9/en active Active
- 2016-09-30 CN CN201680069542.1A patent/CN108290953B/zh active Active
- 2016-09-30 CA CA3000564A patent/CA3000564A1/en active Pending
- 2016-09-30 DK DK16774691.6T patent/DK3368572T3/da active
- 2016-09-30 PL PL16774691.6T patent/PL3368572T3/pl unknown
- 2016-09-30 ES ES16774691T patent/ES2924402T3/es active Active
- 2016-09-30 TW TW105131644A patent/TWI751981B/zh active
- 2016-09-30 MX MX2018003936A patent/MX2018003936A/es unknown
- 2016-09-30 US US15/765,337 patent/US11034765B2/en active Active
- 2016-09-30 KR KR1020187011821A patent/KR20180053752A/ko active Search and Examination
- 2016-09-30 PT PT167746916T patent/PT3368572T/pt unknown
- 2016-09-30 HU HUE16774691A patent/HUE059788T2/hu unknown
- 2016-09-30 EP EP22174837.9A patent/EP4105235A1/en active Pending
- 2016-09-30 WO PCT/EP2016/073421 patent/WO2017055547A1/en active Application Filing
- 2016-09-30 BR BR112018006257A patent/BR112018006257A2/pt active Search and Examination
- 2016-09-30 AU AU2016333517A patent/AU2016333517B2/en active Active
- 2016-09-30 JP JP2018516765A patent/JP6875385B2/ja active Active
- 2016-09-30 LT LTEPPCT/EP2016/073421T patent/LT3368572T/lt unknown
- 2016-09-30 RS RS20220762A patent/RS63490B1/sr unknown
-
2018
- 2018-03-20 ZA ZA2018/01852A patent/ZA201801852B/en unknown
- 2018-04-02 CO CONC2018/0003500A patent/CO2018003500A2/es unknown
- 2018-04-02 SA SA518391262A patent/SA518391262B1/ar unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181044A1 (es) | Anticuerpos anti-pd-1 y composiciones | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
| EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
| PE20221262A1 (es) | Anticuerpos terapeuticos y sus usos | |
| MX2021011697A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123. | |
| PE20190976A1 (es) | Anticuerpos de union a cd3 | |
| PE20191034A1 (es) | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15r y fragmentos de anticuerpo pd-1 | |
| PE20181322A1 (es) | Anticuerpo anti-pd1 y sus metodos de uso | |
| PE20200384A1 (es) | Metodo de fabricacion de anticuerpos bispecificos, anticuerpos bispecificos y uso terapeutico de dichos anticuerpos | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| EA201990321A1 (ru) | Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123 | |
| AR105444A1 (es) | Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3) | |
| EA201990285A1 (ru) | Гетеродимерные иммуноглобулиновые конструкции и способы их получения | |
| PE20190450A1 (es) | Anticuerpos anti-pd-1, un metodo de produccion y un metodo para su uso | |
| PE20211291A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| BR112019005316A2 (pt) | anticorpos monoclonais para morte programada 1 (pd-1) | |
| PE20180481A1 (es) | Anticuerpos de union a tau | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| CO2020001654A2 (es) | Proteínas de fijación al antígeno que se fijan a 5t4 y 4-1bb y composiciones y métodos relacionados | |
| AR101753A1 (es) | COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO | |
| EA201890447A1 (ru) | Гуманизированные антитела к рецептору ccr7 | |
| EA201992206A1 (ru) | Моноклональное антитело к pd-l1 | |
| PE20190415A1 (es) | Anticuerpos anti-basigin humanizados y uso de los mismos | |
| UY38672A (es) | Anticuerpo monoclonal que se une específicamente a gitr |